Chitosan-titanium dioxide-glucantime nanoassemblies effects on promastigote and amastigote of Leishmania major

Varshosaz, Jaleh; Arbabi, Bahar; Pestehchian, Nader; Saberi, Sedigheh; Delavari, Mahdi

doi:10.1016/j.ijbiomac.2017.08.177

Cited by 40 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 10 , 45 The high surface area to volume ratio of nanoparticles may lead to an increase in the area of contact with parasites to mediate the antileishmanial effect. 24 The limitations of current therapeutic drugs coupled with the absence of any effective vaccine and the remarkable activity of GNP against various Leishmania species 27 , 28 , 46 prompted us to investigate its potential against L. donovani . Few studies have investigated the efficacy of GNP against the visceralizing species, L. donovani .…”

Section: Discussionmentioning

confidence: 99%

Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles

Want¹,

Yadav²,

Khan³

et al. 2021

IJN

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles

Want¹,

Yadav²,

Khan³

et al. 2021

IJN

View full text Add to dashboard Cite

“…The activity of the nanoparticles was checked via a UV spectrophotometer. The formulation was found to be effective against amastigote as well as promastigote forms of the parasite [92]. Overall, metallic and metal oxide nanoparticles provide a promising approach for the reduction and treatment of all types of leishmanial activity [92,103].…”

Section: Metallic Nanoparticlesmentioning

confidence: 99%

“…The stability and sustained drug release were also ensured by the LNs. The LN oral drugs have been developed with advancements in technology [92].…”

Section: Lipid Nano-capsulesmentioning

confidence: 99%

Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

et al. 2019

View full text Add to dashboard Cite

Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350 million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but they had toxic side effects. Various nanotechnology-based techniques and products have emerged as anti-leishmanial drugs, including liposomes, lipid nano-capsules, metal and metallic oxide nanoparticles, polymeric nanoparticles, nanotubes and nanovaccines, due to their unique properties, such as bioavailability, lowered toxicity, targeted drug delivery, and biodegradability. Many new studies have emerged with nanoparticles serving as promising therapeutic agent for anti-leishmanial disease treatment. Liposomal Amphotericin B (AmB) is one of the successful nano-based drugs with high efficacy and negligible toxicity. A new nanovaccine concept has been studied as a carrier for targeted delivery. This review discusses different nanotechnology-based techniques, materials, and their efficacies in leishmaniasis treatment and their futuristic improvements.

show abstract

“…Nanoassemblies of chitosan-titanium dioxide (TiO 2 ) nanoparticles (NPs) loaded with Glucantime ® were designed for getting an advantage over their possible additive effects against L. major [ 80 ]. The nanoassemblies with the optimal ratio by using 12.5 mg Glucantime ® , 25 mg chitosan, and 6 mg TiO 2 NPs were prepared and characterized for their physico-chemical characteristics, and mainly loading and release efficiency of drug from nanoassemblies.…”

Section: Chitosan-based Drug Loaded Formulations For the Chemothermentioning

confidence: 99%

“…When evaluated in vitro against L. major promastigotes, TiO 2 NPs exhibited similar activity as those with Glucantime ® alone. However, nanoassemblies were able to decrease both promastigote and intramacrophage amastigote proliferation by 13 and four times, respectively, compared to Glucantime ® alone, after a three-day exposure at 50 µg/mL final concentration [ 80 ].…”

Section: Chitosan-based Drug Loaded Formulations For the Chemothermentioning

confidence: 99%

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

2020

View full text Add to dashboard Cite

The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via different routes and possessing numerous qualities to be used in the antileishmanial strategies. This review presents recent progress in chitosan research for antileishmanial applications. First data on the mechanism of action of chitosan revealed an optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most efficient form, with an uptake by pinocytosis and an accumulation in the parasitophorous vacuole of Leishmania-infected macrophages. In addition, the immunomodulatory effect of chitosan is an added value both for the treatment of leishmaniasis and the development of innovative vaccines. The advances in chitosan chemistry allows pharmacomodulation on amine groups opening various opportunities for new polymers of different size, and physico-chemical properties adapted to the chosen routes of administration. Different formulations have been studied in experimental leishmaniasis models to cure visceral and cutaneous leishmaniasis, and chitosan can act as a booster through drug combinations with classical drugs, such as amphotericin B. The various architectural possibilities given by chitosan chemistry and pharmaceutical technology pave the way for promising further developments.

show abstract

Chitosan-titanium dioxide-glucantime nanoassemblies effects on promastigote and amastigote of Leishmania major

Cited by 40 publications

References 27 publications

Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles

Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles

Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis

Contact Info

Product

Resources

About